Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811327 | 0.90 | GAA (0.33) | GAA | |
| SCHEMBL1685577 | 0.84 | GAA (0.34) | GAA | |
| SCHEMBL4295086 | 0.82 | ADRB3 (0.31) | GAA | |
| SCHEMBL3373246 | 0.79 | GAA (0.34) | GAA | |
| SCHEMBL3814044 | 0.77 | GAA (0.34) | GAA | |
| SCHEMBL16242435 | 0.77 | EPHX2 (0.33) | — | |
| SCHEMBL996970 | 0.76 | MCHR1 (0.33) | GAA | |
| SCHEMBL1645089 | 0.74 | F2 (0.37) | GAA | |
| SCHEMBL3809696 | 0.74 | — | — | |
| SCHEMBL3059428 | 0.73 | NAAA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283018-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2089385-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2086994-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| EP-2089385-A2 | INHIBITORS OF HEPATITIS C VIRUS | Brystol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2086994-A2 | INHIBITORS OF HEPATITIS C VIRUS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2086967-A2 | INHIBITORS OF HEPATITIS C VIRUS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008057873-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057875-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057871-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | GAA 175/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | GAA 1693/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | GAA 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.